Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval
Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from Iovance, and discusses Replimune's plans to file for accelerated approval.